In Vivo Toxicology Market Value By Product Type (Consumables, Instruments), By Test (Sub-acute, Acute, Sub-chronic, Chronic test type), By End User (Contract Research Organizations, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Industry Analysis, Share & Forecast, 2023 - 2032

Market Overview:

In Vivo Toxicology Market size exceeded USD 4.9 Billion in 2022 and is expected to showcase a CAGR of over 5.3% from 2023 to 2032. By the end of the forecast period, the market is anticipated to reach a valuation of around USD 10.1 Billion.

In vivo toxicology is a branch of toxicology that involves the study of the effects of toxic substances on living organisms. In this field, scientists use living organisms such as animals or plants to study the toxic effects of chemicals, drugs, or other substances in a controlled environment. The aim of in vivo toxicology is to understand how these substances interact with biological systems and how they affect the health and well-being of living organisms. 

To get more info about this report - 

In vivo toxicology studies are often carried out to determine the safety and efficacy of new drugs, cosmetics, food additives, and other chemicals before they are approved for use in humans or animals. Researchers typically expose the test subjects to different doses of the substance being studied and monitor them for any adverse effects. The results of these studies can help to inform regulatory decisions and ensure that the products we use are safe for both humans and the environment.

Driver:

Growing demand for in vivo toxicology testing in pharmaceutical and biotech companies:

The growing demand for in vivo toxicology testing in pharmaceutical and biotech companies is one of the key drivers of the in vivo toxicology market. This demand is driven by several factors, including the need for drug development and safety testing, the increasing complexity of drug targets and disease mechanisms, and regulatory requirements for preclinical testing.

Restraint:

High costs associated with in vivo toxicology testing:

The high costs associated with in vivo toxicology testing can be a significant restraint for the market. In vivo testing requires extensive resources, including specialized facilities, equipment, and trained personnel, which can drive up the cost of testing. 

Additionally, the use of animals in testing can add to the costs, as animals must be housed, fed, and cared for throughout the testing process. Furthermore, high costs of this testing can be a barrier for smaller companies and academic researchers who may not have the resources to conduct extensive testing. This can limit innovation and drug development, as promising drug candidates may be abandoned due to lack of funding or resources for in vivo testing.

By Product Synopsys:

The consumable segment is projected to be the fastest emerging segment over the forecast period

Consumables are products that are used or consumed quickly and must be replaced on a regular basis, such as reagents, kits, and test systems. In vivo toxicology testing is an important part of the drug development process because the pharmaceutical industry is constantly developing new drugs. As a result, the demand for consumables used in these tests has increased.

Regional Overview:

North America in vivo toxicology market hold largest revenue share, owing to the presence of major pharmaceutical and biotech companies in the region. The market is also driven by the stringent regulatory environment and the high demand for new drugs and therapies. In addition, the increasing focus on personalized medicine is expected to boost the demand for in vivo toxicology testing in the region however, The Asia-Pacific region is a rapidly growing market for in vivo toxicology testing, driven by the increasing demand for new drugs and therapies in the region. 

The market is also boosted by the presence of emerging biotech companies, as well as the growing outsourcing of drug development and testing to countries such as India and China.

Key Development:

• In September 2021, Charles River Laboratories has introduced a new testing platform for detecting residual host cell DNA in biological drugs. In-Vivo DNA Clearance is a platform that will assist biopharmaceutical companies in ensuring the purity and safety of their products.
   
• In 2020, Taconic has agreed to distribute humanized ACE2 mice for COVID-19 research with the University of Texas Medical Branch.

Top companies include in the global in vivo toxicology market are:

• THE JACKSON LABORATORY
• Envigo
• Charles River Laboratories,
• Taconic Biosciences, Inc.
• genOway
• Bruker Corporation
• Danaher Corporation
• Waters Corporation
• Thermo Fisher Scientific
• Agilent Technologies
• Shimadzu Corporation
• Other Players

To get more info about this report - 

In-depth analysis of in vivo toxicology market along with industry coverage and forecasting for the following segments:

Market Value, By Product Type

• Consumables
• Instruments
• Market Value, By Test
• Sub-acute
• Acute
• Sub-chronic
• Chronic test type

Market Value, By Toxicity End Point

• Carcinogenecity
• Immunotoxicity
• Genotoxicity
• Systemic Toxicity
• Development and Reproductive Toxicity
• Other  

Market Value, By End User

• Contract Research Organizations
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Market Value, By Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America